Cancer Research and Treatment

Low-Dose Whole Brain Radiotherapy with Tumor Bed Boost after Methotrexate-Based Chemotherapy for Primary Central Nervous System Lymphoma: Byoung Hyuck Kim, Il Han Kim, Sung-Hye Park, Chul Kee Park, Hee Won Jung, Tae Min Kim, Se-Hoon Lee, Dae Seog Heo; Cancer Res Treat. 2014;46(3):261-269. Published online July 15, 2014; DOI: https://doi.org/10.4143/crt.2014.46.3.261

Purpose
The purpose of this study is to evaluate the outcome of low-dose whole brain radiotherapy (WBRT) with tumor bed boost after methotrexate-based chemotherapy in the management of primary central nervous system lymphoma (PCNSL). Materials and Methods We retrospectively analyzed 64 patients with pathologically proven PCNSL between 2000 and 2011. Methotrexate-based chemotherapy with a median of five cycles was followed by radiotherapy to the whole brain and to the initial tumor bed. The median dose to the whole brain and to the tumor bed was 27 Gy (range, 18 to 36 Gy) and 50.4 Gy (range, 45 to 54 Gy), respectively. Results With a median follow-up period of 27 months, 55 patients (85.9%) achieved complete response (CR). The 5-year overall survival (OS) and progression-free survival (PFS) rates were 52.6% and 39.3%, respectively. In univariate analysis, factors associated with OS were age, performance status, involvement of deep structure, and CR to sequential chemoradiotherapy (CRT). These variables remained as significant factors for OS in multivariate analysis. CR to sequential CRT was the only positive factor associated with PFS (p=0.009). Neurologic toxicity was more common in elderly patients older than 60 years (p=0.025). Conclusion Low-dose WBRT with tumor bed boost after methotrexate-based chemotherapy might be an effective method for management of PCNSL.

Citations

Citations to this article as recorded by

A narrative review of consolidation strategies for young and fit patients with newly-diagnosed primary central nervous system lymphoma
Sara Steffanoni, Teresa Calimeri, Nicoletta Anzalone, Sara Mastaglio, Massimo Bernardi, Andrés JM Ferreri
Expert Review of Hematology.2022; 15(1): 33. CrossRef
Analysis of Key Factors Associated with Response to Salvage High-Dose Methotrexate Rechallenge in Primary Central Nervous System Lymphoma with First Relapse
Peng Du, Hongyi Chen, Li Shen, Xiao Liu, Xuefan Wu, Lang Chen, Aihong Cao, Daoying Geng
Current Oncology.2022; 29(9): 6642. CrossRef
Cytoreductive Surgery for Primary Central Nervous System Lymphoma: Is it time to consider extent of resection?
Shaani Singhal, Ellathios Antoniou, Edward Kwan, Gareth Gregory, Leon T. Lai
Journal of Clinical Neuroscience.2022; 106: 110. CrossRef
Role of 23.4 Gy upfront whole-brain radiation therapy following high-dose methotrexate for primary central nervous system lymphoma: a comparative analysis of whole-brain radiation therapy versus no radiation therapy
Nalee Kim, Do Hoon Lim, Sang Eun Yoon, Seok Jin Kim, Won Seog Kim
Journal of Neuro-Oncology.2021; 154(2): 207. CrossRef
Nanomedicine Applications in Treatment of Primary Central Nervous System Lymphoma: Current State of the Art
Mengyao Wang, Ying Qu, Danrong Hu, Ting Niu, Zhiyong Qian
Journal of Biomedical Nanotechnology.2021; 17(8): 1459. CrossRef
Reduced-dose whole-brain radiotherapy with tumor bed boost after upfront high-dose methotrexate for primary central nervous system lymphoma
Tae Hoon Lee, Joo Ho Lee, Ji Hyun Chang, Sung-Joon Ye, Tae Min Kim, Chul-Kee Park, Il Han Kim, Byoung Hyuck Kim, Chan Woo Wee
Radiation Oncology Journal.2020; 38(1): 35. CrossRef
Advances and challenges in the treatment of primary central nervous system lymphoma
Hua Yang, Yang Xun, Anping Yang, Fang Liu, Hua You
Journal of Cellular Physiology.2020; 235(12): 9143. CrossRef
Whole brain radiation dose reduction for primary central nervous system lymphoma patients who achieved partial response after high-dose methotrexate based chemotherapy
Jun Su Park, Do Hoon Lim, Yong Chan Ahn, Won Park, Seok Jin Kim, Won Seog Kim, Kihyun Kim
Japanese Journal of Clinical Oncology.2017; 47(11): 995. CrossRef
Role of radiation therapy in primary central nervous system lymphoma
Hyeon Kang Koh, Il Han Kim, Tae Min Kim, Do Hoon Lim, Dongryul Oh, Jae Ho Cho, Woo-Chul Kim, Jin Hee Kim, Woong-Ki Chung, Bae-Kwon Jeong, Ki Mun Kang, Semie Hong, Chang-Ok Suh, In Ah Kim
Journal of Neuro-Oncology.2017; 135(3): 629. CrossRef

12,590 View
77 Download
10 Web of Science
9 Crossref

Germline Mutations of the NF2 Gene in Korean Neurofibromatosis 2 Patient: Hee Jin Yang, Yong Jin Won, Kyu Joo Park, Hee Won Jung, Kil Soo Choi, Jae Gahb Park; J Korean Cancer Assoc. 1998;30(4):790-799.

Abstract PDF: PURPOSE
Neurofibromatosis 2(NF2) is an autosomal dominant disease characterized by development of bilateral acoustic neuroma and various central nervous system tumors such as meningiomas, ependymomas, and schwannomas. Recent cloning of the gene responsible for NF2, the NF2 gene, permits the presymptomatic genetic diagnosis of affected individuals by direct analysis of the gene. This paper was intended to identify germline mutations in Korean NF2 patients.
MATERIALS AND METHODS
We collected blood samples from 15 clinically diagnosed NF2 patients treated at the Department of Neurosurgery, Seoul National University Hospital. Purified genomic DNA samples were analyzed for mutations of the NF2 gene by using polymerase chain reaction(PCR)-single strand conformation polymorphism(SSCP) method followed by direct DNA sequencing.
RESULTS
We were able to identify germline mutation of the NF2 gene in one patient. The mutation identified was 1 base pair deletion(A) at codon 318, resulting in premature stop codon due to frameshift.
CONCLUSION
Identification of the germline mutation in NF2 gene should enable us to test all individual family members at risk to determine whether or not they carry the mutant NF2 gene.

2,669 View
20 Download

Phase III Randomized Trial of ACNU in Addition to Surgery and Radiotherapy for Patients with Supratentorial Malignant Gliomas: Hee Won Jung, Chang Wan Oh, Chun Kee Chung, Hee Jin Yang, Kil Soo Choi, Dae Hee Han, Je G Chi, Yung Jue Bang, Dae Seog Heo, Noe Kyeong Kim, Yoon Ok Ahn, Il Han Kim; J Korean Cancer Assoc. 1997;29(4):608-615.

Abstract PDF: No abstract available

2,507 View
16 Download

Germline Mutations of VHL gene in Korean von Hippel - Lindau Disease Patients: Ki Hyuk Shin, Kyu Joo Park, Soo Woong Kim, Sang Hoon Lee, Sang Eun Lee, Hee Won Jung, Hyun Jip Kim, Jae Gahb Park; J Korean Cancer Assoc. 1996;28(3):544-555.

Abstract PDF: Von Hippel-Lindau(VHL) disease is an autosomal dominant disease characterized by development of different tumors in diverse organs, including hemangioblastoma of the central nervous system, renal cell carcinoma, pheochromocytoma, and pancreatic tumors. The gene responsible for this disease, the VHL gene, was recently cloned and germline mutations of this gene identified in patients with VHL. Using polymerase chain reaction(PCR)-single strand conformation polymorphism(SSCP) analysis followed by DNA sequencing, we were able to identify germline mutations of the VHL gene in two unrelated Korean patients exhibiting typical clinical features of the VHL disease. The mutations identified were 2 base pair deletion at codon l79 in one patient, and a missense mutation at codon 190 in the other. Identification of the germline mutation in VHL gene aids in the accurate presymptomatic diagnosis of the at-risk family members of these patients.

2,916 View
25 Download

Search